Ki20227

SYN-1049



(N-{4-[(6,7-dimethoxy-4-quinolyl)oxy]-2-methoxyphenyl}-N'-[1-(1,3-thiazole-2-yl)ethyl]urea)

CAS Registry No.: 623142-96-1

Smiles String:
CC(c1nccs1)NC(=O)Nc2ccc(cc2OC)Oc3ccnc4c3cc(c(c4)OC)OC

Molecular Weight: 480.54

Molecular Formula: C24H24N4O5S

Lot Number: Refer to vial

1H-NMR: Available on request

HPLC (Purity): > 95.0% @ 254 nm

ES-MS: Available on request

Description:

Ki20227 is a c-fms tyrosine kinase inhibitor. It has IC50 values of 2, 12, 451 and 217 nM for c-Fms, VEGFR-2, c-Kit and PDGFRbeta respectively.

Biological Activity



Kinome Mapping



Shipping and Storage Temperature

Shipping:
Ambient

Storage:
2 years -20C, Powder 1 month, -4C in DMSO, More than one month -80C in DMSO

Solubility

DMSO 10mg/mL, Ethanol 4mg/mL

Preparing Stock Solutions

Stock Solution (1ml DMSO)	1mM	10mM	20mM	50mM
Mass(mg)	0.4806	4.8060	9.6120	24.0300

References

1. Ohno H, Kubo K, Murooka H, Kobayashi Y, Nishitoba T, Shibuya M, Yoneda T, Isoe T . A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol Cancer Ther. 2006 Nov;5(11):2634-43.

2. Ohno H, Uemura Y, Murooka H, Takanashi H, Tokieda T, Ohzeki Y, Kubo K, Serizawa I . The orally-active and selective c-Fms tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen-induced arthritis mouse model. Eur J Immunol. 2008 Jan;38(1):283-91.

3. Kubota Y, Takubo K, Shimizu T, Ohno H, Kishi K, Shibuya M, Saya H, Suda T . M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J Exp Med. 2009 May 11;206(5):1089-102. doi: 10.1084/jem.20081605. Epub 2009 Apr 27.

Ordering Information

To order more of this or any other SYNkinase compound, go to synkinase.com, Call us Toll Free (US Only) at 1- 877-854-6273 or email orders@synkinase.com.